Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May-Jun;19(3):404-411.
doi: 10.1016/j.jacl.2025.02.019. Epub 2025 Feb 27.

JCL Roundtable: Prediabetes

Kevin C Maki  1 , Carol F Kirkpatrick  2 , Jaime Almandoz  3
Affiliations

JCL Roundtable: Prediabetes

Kevin C Maki et al. J Clin Lipidol. 2025 May-Jun.

Abstract

Prediabetes affects more than 1 in 3 adults in the United States and is associated with increased risks of type 2 diabetes, cardiovascular diseases, chronic kidney disease, and dementia. Excess adiposity is the strongest risk factor for prediabetes, and can contribute to several other cardiometabolic risk factors, such as dyslipidemia and insulin resistance. This Journal of Clinical Lipidology Roundtable presents a conversation between Drs Jaime P. Almandoz, Carol F. Kirkpatrick, and Kevin C. Maki, who discussed lifestyle and pharmacologic interventions for the management of prediabetes and the prevention of associated health risks. The discussion highlights the importance of interventions for addressing excess adiposity in those with prediabetes, including lifestyle, pharmacotherapy, and metabolic surgery, along with involving patients in shared decision-making conversations to identify, implement, and maintain an effective treatment plan.

Keywords: Adiposity; Antiobesity medications; Cardiometabolic health; Lifestyle interventions; Obesity; Prediabetes.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest Jaime P. Almandoz received consulting fees from AbbVie, Boehringer Ingelheim, Eli Lilly & Co., Nestlé, Novo Nordisk A/S, and Wave Life Sciences; received payment or honoraria for lectures from Clinical Care Options, the Institute for Medical and Nursing Education, Vindico, and PeerView; and served in a leadership or fiduciary role with The Obesity Society Governing Board and the Board of Directors of the American Board of Obesity Medicine. Carol F. Kirkpatrick is an employee of Midwest Biomedical Research, which has received research funding and consulting fees from food and pharmaceutical companies; no other disclosures. Kevin C. Maki is an employee of Midwest Biomedical Research and Indiana University and has received research grant support from Cargill, General Mills, Global Organization for EPA and DHA, Greenyn Biotechnology, Hass Avocado Board, Helaina, Indiana University Foundation, Matinas BioPharma, MD Lifespan, Medifast, National Cattlemen's Beef Association/Beef Checkoff, National Dairy Council, Naturmega, NewAmsterdam Pharma, Novo Nordisk, PepsiCo, and Pharmavite; and received consulting fees from and/or served on advisory boards of 89Bio, Acasti Pharma, Beren Therapeutics, Bragg Live Products, Campbell's, Eli Lilly & Co., Helaina, Lonza Group, Matinas BioPharma, MD Lifespan, National Cattlemen's Beef Association, National Dairy Council, NewAmsterdam Pharma, NorthSea Therapeutics, Novo Nordisk, Seed Inc, and Soy Nutrition Institute Global.

LinkOut - more resources